Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

What to prefer in 2023: Europe or America?

Mon, 12th Dec 2022 10:48

STOXX down 0.4%, volatility hits 1-mo high

*

Caution ahead of central bank meetings

*

CHR Hansen rallies on Novozymes merger

*

U.S. stock index futures inch higher

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

WHAT TO PREFER IN 2023: EUROPE OR AMERICA? (1043 GMT)

With European stocks heading into 2023 at a near-record discount to their Wall Street peers, the evergreen question of which market will beat the other looks more alive than ever.

Bernstein is betting on the Old World.

It believes investors should tactically overweight the region versus the U.S., principally based on expectations of a bigger potential of multiple expansion in Europe.

"If one assumes a benign scenario where inflation has peaked and that central banks remain careful but don't get much more hawkish, and that the energy crisis does not worsen from here, our view is that Europe is in a better position for multiple expansion," say Bernstein's Sarah McCarthy and Mark Diver.

According to Bernstein, Europe and the U.S. should both see further earnings cuts. But as markets typically bottom out a couple of months before earning cuts do, this should set the scene for recovery.

Add to that a higher rate environment, which tends to be tougher for growth-oriented regions like the U.S., and the extremely depressed sentiment around Europe, then Bernstein's case for Europe is clear.

Europe has seen outflows since 2016, whereas the U.S. has received strong inflows since end-2020, Bernstein says. In 2022 alone, investors have pulled out $100 billion from European equity funds and poured over $200 billion into the U.S..

According to Refinitiv Datastream, the MSCI Europe index trades at near record PE discount of 33.6% relative to the MSCI USA. That is well below the 5-year average discount of 23.7%.

And in in term of price perfomance, MSCI Europe trades just above the record low relative the MSCI USA hit in September.

VOLATILITY PICKS UP, STOXX DIPS (0906 GMT)

Caution over a flurry of fresh rate hikes this week, which will tighten financial conditions even further, was tangible in early trading in Europe with a gauge of equity volatility hitting a one-month high as the STOXX 600 benchmark slid.

The pan-European index was last down 0.7%, partly reversing Friday's gains, and the euro volatility index, a local equivalent of Wall Street's so-called fear gauge VIX , approached 23 points and hit its highest since Nov. 10. Most STOXX sectors were in the red, led by rate-sensitive real estate, down more than 2%.

Deal-making gave fuel to the biggest stock movers. CHR Hansen soared 36% at one point after the Danish food ingredients and enzymes maker was valued at a premium in a merger deal with peer with Novozymes.

London Stock Exchange was the second biggest gainer on the STOXX, up around 4%, following a cloud deal with Microsoft that saw the U.S. tech group taking a stake in the UK bourse operator.

Momentum continued for aerodefence plays set to benefit from higher military spending. A sectoral gauge surged to its highest since February 2020, up 0.8% to defy the broader weakness. Here is your opening snapshot:

EUROPE SEEN WEAKER AS MORE RATE HIKES LOOM (0740 GMT)

European shares are set to kick off a macro-packed week on the back foot, tracking Friday's late losses on Wall Street and weakness earlier in Asia, where spreading COVID cases in China added to the downbeat mood.

EuroSTOXX50, DAX and FTSE futures fell between 0.3 and 0.5%, while the MSCI's broadest index of Asia-Pacific shares outside Japan fell 1.3%. U.S. futures meanwhile pointed to softer start on Wall Street.

On the European corporate news front, shares in London Stock Exchange will be in focus after Microsoft agreed to take 4% in the UK exchange operator as part of deal to migrate the bourse operator's data platform into the cloud.

Eyes also on Sanofi after the French health group dropped plans to bid for Horizon Therapeutics, while in Italy, Tod's founder ditched plans to delist the shoemaker after a buy-out that didn't meet a key threshold.

Still in M&A, Superdry is another one to watch after the Sunday Times reported CEO and founder Julian Dunkerton has held talks with private equity firms about a possible buyout.

HUNKERING DOWN (0659 GMT)

Just as China faces a testing time over its dramatic COVID-19 policy pivot, financial markets are on full alert ahead of interest rate decisions coming out this week from the world's top central banks.

Initial market enthusiasm over China's easing of its stringent "zero-COVID" measures has now switched to worries over a wave of infections likely disrupting the economy.

European stock markets are set for a weaker start on Monday, dragged by declines in Asian stocks, with the spotlight on a series of central bank meetings even as expectations rise that euro zone inflation is peaking.

The European Central Bank is set to take its deposit rate up by 50 basis points to 2%, despite the euro zone economy almost certainly being in recession, as it battles inflation running at five times its target, a Reuters poll found.

It's a Super Thursday this week, with the ECB, Bank of England, and the Swiss and Norwegian central banks also expected to jack up borrowing costs. What markets are keen to find out is whether they are nearly done.

On Sunday, U.S. Treasury Secretary Janet Yellen forecast a substantial reduction in U.S. inflation in 2023, barring an unexpected shock.

Whether inflation is responding to the most aggressive Fed hiking cycle since the 1980s will be evident in this week's U.S. consumer price index report. On the corporate front, while French health group Sanofi announced it had dropped its bid for biotech company Horizon Therapeutics, the Wall Street Journal reported that Amgen is in advanced talks to buy Horizon.

Meanwhile, a consolidation is shaping up in the food delivery market as Turkish delivery company Getir bought German rival Gorillas in a deal worth $1.2 billion, merging two of the remaining companies in Europe promising groceries in minutes.

Key developments that could influence markets on Monday:

Economic data: UK October GDP and industrial output

More News
10 Jul 2023 19:33

EU investigates Ozempic, weight-loss drug Saxenda after suicidal thoughts reported

July 10 (Reuters) - The European Medicines Agency (EMA) is investigating Novo Nordisk's diabetes drug Ozempic and weight-loss treatment Saxenda after Iceland's health regulator flagged three cases of patients thinking about suicide or self-harm.

Read more
5 Jul 2023 12:04

China extends squeezed-out foreign pharmaceuticals firms an olive branch

BEIJING, July 5 (Reuters) - China's Commerce Minister told foreign pharmaceuticals firms they can expect "more development opportunities" during a roundtable on Wednesday, his ministry said, as drugmakers bemoan government procurement policies pricing them out of the market.

Read more
30 Jun 2023 22:38

First trial over Zantac cancer claims set for November

June 30 (Reuters) - The first U.S. trial over claims that discontinued heartburn drug Zantac causes cancer is now expected to take place in California state court on Nov. 13, a lawyer for plaintiffs in the litigation said Friday.

Read more
29 Jun 2023 06:30

Sanofi says it's back to the drawing board on mRNA flu vaccines

June 29 (Reuters) - Sanofi said that trials show the currently available mRNA technology behind the most successful COVID-19 shots will not be effective against influenza and it is already working on a next generation of shots.

Read more
23 Jun 2023 20:24

GSK soothes investors by settling first Zantac cancer lawsuit due for US trial

GSK shares best performer on London's stock market

*

Read more
22 Jun 2023 14:02

Novo Nordisk says EMA raised safety signal on drugs including semaglutide

Signal included drugs from Eli Lilly, AstraZeneca, Sanofi

*

Read more
22 Jun 2023 08:54

Novo Nordisk shares slip on EMA drug safety signal

COPENHAGEN, June 22 (Reuters) - Novo Nordisk said on Thursday the European Union's drug watchdog had last month raised a thyroid cancer safety signal for several of its drugs including semaglutide, the active ingredient in its popular diabetes and obesity drugs, Ozempic and Wegovy.

Read more
20 Jun 2023 17:44

China-exposed miners, luxury shares drag STOXX 600 down; Lanxess plunges

China-exposed miners and luxury stocks weigh

*

Read more
31 May 2023 23:35

US FDA approves Pfizer's RSV vaccine

May 31 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors.

Read more
27 Apr 2023 12:36

AstraZeneca increases bets on China as COVID vaccine sales fade

AstraZeneca already biggest drugmaker in China

*

Read more
27 Mar 2023 23:51

Amgen-Sanofi patent case divides makers of antibody drugs

March 27 (Reuters) - Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.

Read more
24 Mar 2023 15:25

GSK loses bid to keep experts out of upcoming Zantac trial

March 24 (Reuters) - A California judge on Thursday denied GSK Plc's bid to keep expert testimony linking its discontinued heartburn drug Zantac to cancer out of an upcoming trial, a setback for the British drugmaker facing lawsuits over the medicine in courts across the United States.

Read more
23 Mar 2023 17:09

Banks drag European shares down as c.banks join Fed in raising rates

Banks down 2.4%, rate-sensitive tech up 2.2%

*

Read more
20 Mar 2023 06:00

Vaccine makers prep bird flu shot for humans 'just in case'; rich nations lock in supplies

LONDON, March 20 (Reuters) - Some of the world's leading makers of flu vaccines say they could make hundreds of millions of bird flu shots for humans within months if a new strain of avian influenza ever jumps across the species divide.

Read more
13 Mar 2023 17:13

European stocks log steepest one-day fall this year as banks extend slide

European banks log worst two-day selloff in a year

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.